Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810160 · ClinicalTrials.gov registry record · Phase 1
The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants
A Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT00810160: Completed Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant, sponsored by University of California, Davis.
NCT00810160 is a Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant that has completed, run by University of California, Davis. The registered enrollment target is 59 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00810160, a Phase 1 study of Fecal Microflora in the Formula Fed Premature Infant, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see whether dietary supplements can change the germs in the intestines of premature infants to be more like those of healthy breast fed term babies.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT ProlactPlus
- DIETARY_SUPPLEMENT GOS galacto-oligosaccharides
- DIETARY_SUPPLEMENT Bifidobacterium infantis
- DIETARY_SUPPLEMENT Bifidobacterium animalis
Study Locations (1)
California
- UC Davis Medical Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
What the finished NCT00810160 record still lists
NCT00810160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Fecal Microflora in the Formula Fed Premature Infant appearing as the primary indexed condition, and to 4 interventions - of which ProlactPlus is the first listed.
NCT00810160 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00810160 about?
NCT00810160 is a clinical study titled "The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants". The purpose of this study is to see whether dietary supplements can change the germs in the intestines of premature infants to be more like those of healthy breast fed term babies.
What is the current status of trial NCT00810160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-06. Estimated completion is 2015-11.
What conditions does trial NCT00810160 study?
This clinical trial studies the following conditions: Fecal Microflora in the Formula Fed Premature Infant.
What interventions are being tested in trial NCT00810160?
The interventions under investigation include: ProlactPlus (DIETARY_SUPPLEMENT), GOS galacto-oligosaccharides (DIETARY_SUPPLEMENT), Bifidobacterium infantis (DIETARY_SUPPLEMENT), Bifidobacterium animalis (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00810160?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810160 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00810160's enrollment target sits among peer trials
59 895th of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia